Novo Nordisk

Official website ↗

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S (wholly owned by the Novo Nordisk Foundation) which holds approximately 28.1% of its shares and a majority (77.1%) of its voting shares. Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes and obesity medications and devices. Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo Nordisk is the largest pharmaceutical company in Denmark. Novo Nordisk's market capitalization exceeded the GDP of Denmark's domestic economy in 2023, and it is the highest valued company in Europe. Net sales in 2024 were US$42.121 billion.

Source: https://www.novonordisk.com/about.html

insulin aspartNovoLog

rapid-acting insulin analogue

NovoLog (insulin aspart) is a rapid-acting insulin from Novo Nordisk. A single amino acid change makes it absorb quickly after injection, so it covers the rise in blood sugar that follows a meal, and it is used in type 1 and type 2 diabetes.

Insulin is the hormone that lets cells absorb glucose from the blood. After a meal, blood sugar rises quickly, and the body needs a fast burst of insu

insulin degludecTresiba

long-acting insulin analogue

Tresiba (insulin degludec) is an ultra-long-acting basal insulin from Novo Nordisk. After injection it forms multi-hexamer chains under the skin that release insulin steadily for more than 24 hours, providing a stable, peakless background level for diabetes control.

Insulin is the hormone that lets cells absorb glucose from the blood. People with type 1 diabetes make none, and many with type 2 diabetes eventually

liraglutideVictoza

GLP-1 receptor agonist

Victoza (liraglutide) is a once-daily GLP-1 receptor agonist from Novo Nordisk for type 2 diabetes. A fatty acid tail keeps it in the blood for about a day, boosting meal-time insulin, calming glucagon and slowing stomach emptying to lower blood sugar.

Liraglutide copies the action of GLP-1, a hormone released after eating. It stimulates insulin release when blood sugar is high, reduces glucagon, whi

semaglutideOzempic

GLP-1 receptor agonist

Ozempic (semaglutide) is a GLP-1 receptor agonist from Novo Nordisk for adults with type 2 diabetes. Alongside diet and exercise it improves blood sugar control, reduces major cardiovascular events in people with established cardiovascular disease, and protects kidney function in chronic kidney disease.

Semaglutide belongs to the incretin mimetic class. It mimics the gut hormone GLP-1, which is normally released after meals. By activating GLP-1 recept